It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Despite an unprecedented global gain in knowledge since the emergence of SARS-CoV-2, almost all mechanistic knowledge related to the molecular and cellular details of viral replication, pathology and virulence has been generated using early prototypic isolates of SARS-CoV-2. Here, using atomic force microscopy and molecular dynamics, we investigated how these mutations quantitatively affected the kinetic, thermodynamic and structural properties of RBD—ACE2 complex formation. We observed for several variants of concern a significant increase in the RBD—ACE2 complex stability. While the N501Y and E484Q mutations are particularly important for the greater stability, the N501Y mutation is unlikely to significantly affect antibody neutralization. This work provides unprecedented atomistic detail on the binding of SARS-CoV-2 variants and provides insight into the impact of viral mutations on infection-induced immunity.
Here, the authors combine single-molecule atomic force spectroscopy measurements and molecular dynamics simulations to investigate the binding of spike proteins from four SARS-CoV-2 variants of concern (VoC) to the human ACE2 receptor. They observe an increase in the RBD-ACE2 complex stability for several of the VoCs and derive how the mutations affect the kinetic, thermodynamic and structural properties of complex formation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 Université catholique de Louvain, Louvain Institute of Biomolecular Science and Technology, Louvain-la-Neuve, Belgium (GRID:grid.7942.8) (ISNI:0000 0001 2294 713X)
2 Polish Academy of Sciences, Institute of Fundamental Technological Research, Warsaw, Poland (GRID:grid.413454.3) (ISNI:0000 0001 1958 0162)
3 Lodz University of Technology, International Center for Research on Innovative Biobased Materials (ICRI-BioM)—International Research Agenda, Lodz, Poland (GRID:grid.412284.9) (ISNI:0000 0004 0620 0652)
4 Université catholique de Louvain, Louvain Institute of Biomolecular Science and Technology, Louvain-la-Neuve, Belgium (GRID:grid.7942.8) (ISNI:0000 0001 2294 713X); Walloon Excellence in Life sciences and Biotechnology (WELBIO), Wavre, Belgium (GRID:grid.509491.0)